Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC By Ogkologos - July 9, 2025 619 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Raises Key Issues on Cancer Prevention and Care at the WHO Executive Board Meeting Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French MOST POPULAR “Oncometabolite” Neutralizes Immune Cells Near Tumors November 18, 2022 Seven Ways an Occupational Therapist Can Help Patients Recovering From Breast... April 30, 2021 Coronavirus reports – Part 9: “I am very relieved but I... March 4, 2021 Evaluation of Primary and Secondary Prevention of Oral Cancer October 28, 2022 Load more HOT NEWS Long-Term Responders with No Evidence of Disease Have Better Survival to... Patient Guide on Cancer Pain Management Now Available Also in French First-Line Treatment with Encorafenib Plus Cetuximab Plus mFOLFOX6 Significantly Improves ORR... October is National Dental Hygiene Month
